Clinical Study of Colon Cancer Treated with Different Neoadjuvant Chemotherapy Regimens
DENG Hai-shan, XU Xiao-ping, HANG Tian, et al.
Zhejiang Armed Police Corps Hospital, Jiaxing (314000), China
Abstract:
Objective To observe the effect of two different neoadjuvant chemotherapy regimens combined with surgery in treatment of colon cancer. Methods Totally 42 patients with colon cancer were randomly divided into treatment group (23 cases) and control group (19 cases). Patients in the treatment group received intravenous infusion of oxaliplatin combined with tegafur before operation and received 4 cycles of chemotherapy 2 weeks after operation. The patients in control group received oral administration of oxaliplatin combined with 5-fluorouracil and leucovorin before operation and received 4 cycles of chemotherapy 2 weeks after operation. Follow up for 3 years, from adverse reactions, changes of tumor diameter before and after chemotherapy, operation time, intraoperative bleeding volume, evaluation of curative effect of solid tumor. The efficacy of RECIST was evaluated. Results The diameter of tumor was (25.87±3.37) mm in the treatment group and (26.58±3.83) mm in the control group. The tumor diameter of the treatment group was (17.22±2.2) mm after chemotherapy and (23.00±3.26) mm in control group, with statistical difference between the two groups before and after chemotherapy (P<0.001). There was no difference in operative time and blood loss between the two groups. Conclusion Neoadjuvant chemotherapy is effective in reducing the tumor size of colon cancer. It can be concluded that oxaliplatin combined with tegafur is superior to oxaliplatin combined with FL in reducing bone marrow suppression and incidence of digestive tract reaction and decreasing phase.
